MetaCap

iBio (IBIO) vs Rani Therapeutics (RANI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

iBio (IBIO) has outperformed Rani Therapeutics (RANI) over the past year, losing 23.8% versus a loss of 68.6%. Over five years, RANI leads with a -98.3% price change compared with -99.8% for IBIO. Rani Therapeutics is the larger company by market cap ($59.0 million vs $56.4 million), about 1.0 times the size.

Rani Therapeutics converts more of its revenue into profit, with a net margin of -1817.1% versus -33044.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IBIO-23.80%RANI-68.64%
+205%+62%-82%
Nov 21, 20251 yearNov 20, 2026
IBIO-99.76%RANI-98.50%
+7%-49%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IBIO versus RANI key metrics
MetricIBIORANI
Share price$0.8001$0.5111
Market cap$56.37M$59.03M
1-day change-0.11%-11.97%
YTD return-58.54%-62.14%
1-year return-23.80%-68.64%
5-year return-99.76%-98.34%
EPS (TTM)$-0.27$-0.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$100.00K$1.63M
Revenue growth (YoY)-75.00%+58.85%
Net income (latest FY)$-33.04M$-29.67M
Operating margin-35141.00%-2345.99%
Net margin-33044.00%-1817.09%
52-week high$3.82$1.69
52-week low$0.68$0.502
Distance from 52-week high-79.05%-69.76%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+611.16%+1308.73%
Average volume678.91K545.67K
Shares outstanding70.46M115.49M
Employees2369
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IBIO has outperformed RANI by 44.8 percentage points over the past year.
  • Rani Therapeutics is more profitable, keeping -1817.1 cents of every revenue dollar as net income versus -33044.0 cents for iBio.
  • Rani Therapeutics grew revenue faster in its latest fiscal year (+58.85% vs -75.00%).

About iBio

IBIO stock →

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About Rani Therapeutics

RANI stock →

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

IBIO vs RANI FAQ

Which is bigger, iBio or Rani Therapeutics?

Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $56.37M for iBio (IBIO).

Which stock has performed better over the past year, IBIO or RANI?

IBIO returned -23.80% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.

Are iBio and Rani Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons